Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from OS Therapies Incorporated ( (OSTX) ) is now available.
On March 31, 2026, OS Therapies entered into a securities purchase agreement for a registered direct offering of common stock, pre-funded warrants and common warrants, which closed on April 2, 2026 and delivered approximately $4.7 million in net proceeds. The company also engaged Ceros Financial Services as exclusive placement agent, paying a 7% cash fee and issuing placement agent warrants, while agreeing to short-term restrictions on additional equity issuance and variable-rate financings that temper near-term dilution but limit financing flexibility.
In a concurrent April 2, 2026 announcement, OS Therapies reported completion of a $5.25 million registered direct offering, largely with existing high-net-worth investors, and highlighted an expected additional $4 million in non-dilutive VAT refunds and R&D tax credits from its U.K. subsidiary, which together are projected to fund operations into 2027. Management indicated that this capital position supports planned regulatory submissions and confirmatory Phase 3 work for OST-HER2 across the U.S., U.K., Europe and Australia, potentially strengthening the company’s footing in osteosarcoma immunotherapies if anticipated 2026 approvals and early market access materialize.
The most recent analyst rating on (OSTX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, widening losses and higher 2025 cash burn) and a bearish technical setup (below major moving averages). Recent positive financing activity supports liquidity and offsets some risk, but dilution/financing dependence remains a key overhang, while valuation signals continued losses with no dividend support.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
OS Therapies Inc. is a clinical-stage oncology company focused on developing and commercializing treatments for osteosarcoma and other solid tumors, and is listed on the NYSE American under the ticker OSTX. The company is a leader in listeria-based cancer immunotherapies, with lead asset OST-HER2 targeting the HER2 protein and supported by multiple FDA and EMA designations, alongside a pipeline that includes prostate cancer candidate OST-504 and a tunable ADC platform.
Average Trading Volume: 573,003
Technical Sentiment Signal: Sell
Current Market Cap: $53.77M
Find detailed analytics on OSTX stock on TipRanks’ Stock Analysis page.